Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor: A Case Report

Yusuke Konta; Eiichiro Saito; Koji Sato; Kyohei Furuta; Kenichiro Miyauchi; Akiko Furukawa; Hiroshi Sato; Tae Yamamoto

doi:10.2169/internalmedicine.9011-21

This article has now been updated. Please use the final version.

Tubulointerstitial Nephritis after Using a Sodium-glucose Cotransporter 2 Inhibitor: A Case Report

Yusuke Konta, Eiichiro Saito, Koji Sato, Kyohei Furuta, Kenichiro Miyauchi, Akiko Furukawa, Hiroshi Sato, Tae Yamamoto

Author information

Keywords: acute kidney injury, diabetes mellitus, empagliflozin, sodium-glucose cotransporter 2 inhibitors, tubulointerstitial nephritis

JOURNAL OPEN ACCESS Advance online publication

Article ID: 9011-21

DOI https://doi.org/10.2169/internalmedicine.9011-21

The final version of this article is now available: Vol. 61 (2022), No. 21 pp. 3239-3243

Details

Abstract

We herein report a case of acute kidney injury (AKI) due to tubulointerstitial nephritis (TIN) after starting empagliflozin in a diabetic patient. The patient developed stage 1 AKI with proteinuria and elevated tubulointerstitial markers. A renal biopsy showed acute TIN with lymphocytic infiltration into the interstitium. The patient's renal function improved after discontinuation of empagliflozin and steroid administration. Sodium-glucose cotransporter 2 (SGLT2) inhibitor-induced AKI has been reported, but the underlying mechanism remains unclear, potentially because few patients with SGLT2-inhibitor-induced AKI have undergone a renal biopsy. We report the present case in the hope that it will help clarify the mechanism.

Corresponding author

Register with J-STAGE for free!